It certainly can't harm the potential revenue profile. We need a step change in the monetisation patterns though for this to re-rate.
Ann: US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment, page-4
Add to My Watchlist
What is My Watchlist?
